Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 515

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Metal-based anticancer chemotherapeutic agents

Muhammad, Nafees, Guo, Zijian · 2014 · Current Opinion in Chemical Biology

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cbpa.2014.02.003

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 21

  1. Kozubik, 2005, High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro, Biochem Pharmacol, 69, 373, 10.1016/j.bcp.2004.09.005 · doi:10.1016/j.bcp.2004.09.005
  2. Medrano, 2013, Oxidation of anticancer Pt(II) complexes with monodentate phosphane ligands: towards stable but active Pt(IV) prodrugs, Chem Commun (Camb), 49, 4806, 10.1039/c3cc38416k · doi:10.1039/c3cc38416k
  3. Varbanov, 2012, Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs, Dalton Trans, 41, 14404, 10.1039/C2DT31366A · doi:10.1039/c2dt31366a
  4. Ravera, 2012, Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(IV) complexes based on picoplatin, Dalton Trans, 41, 3313, 10.1039/c2dt11874b · doi:10.1039/c2dt11874b
  5. Pichler, 2013, Bulky N(,N)-(di)alkylethane-1,2-diamineplatinum(II) compounds as precursors for generating unsymmetrically substituted platinum(IV) complexes, Inorg Chem, 52, 8151, 10.1021/ic400816g · doi:10.1021/ic400816g
  6. Farrer, 2010, A potent trans-diimine platinum anticancer complex photoactivated by visible light, Angew Chem Int Ed, 49, 8905, 10.1002/anie.201003399 · doi:10.1002/anie.201003399
  7. Wedlock, 2013, NanoSIMS multi-element imaging reveals internalisation and nucleolar targeting for a highly-charged polynuclear platinum compound, Chem Commun (Camb), 49, 6944, 10.1039/c3cc42098a · doi:10.1039/c3cc42098a
  8. Manzotti, 2000, BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin, Clin Cancer Res, 6, 2626
  9. Zhao, 2006, A positively charged trinuclear 3N-chelated monofunctional platinum complex with high DNA affinity and potent cytotoxicity, Dalton Trans, 2617, 10.1039/b601739h · doi:10.1039/b601739h
  10. Wang, 2011, Noncovalent interactions between a trinuclear monofunctional platinum complex and human serum albumin, Inorg Chem, 50, 12661, 10.1021/ic201712e · doi:10.1021/ic201712e
  11. Zerzankova, 2010, Mechanistic insights into antitumor effects of new dinuclear cis Pt(II) complexes containing aromatic linkers, Biochem Pharmacol, 80, 344, 10.1016/j.bcp.2010.04.013 · doi:10.1016/j.bcp.2010.04.013
  12. Komeda, 2011, A tetrazolato-bridged dinuclear platinum(II) complex exhibits markedly high in vivo antitumor activity against pancreatic cancer, ChemMedChem, 6, 987, 10.1002/cmdc.201100141 · doi:10.1002/cmdc.201100141
  13. Komeda, 2013, Synthesis of antitumor azolato-bridged dinuclear platinum(II) complexes with in vivo antitumor efficacy and unique in vitro cytotoxicity profiles, Metallomics, 5, 461, 10.1039/c3mt00040k · doi:10.1039/c3mt00040k
  14. Brown, 2012, Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity, Dalton Trans, 41, 11330, 10.1039/c2dt31313h · doi:10.1039/c2dt31313h
  15. Lakomska, 2013, Synthesis, characterization and antitumor properties of two highly cytotoxic ruthenium(III) complexes with bulky triazolopyrimidine ligands, Dalton Trans, 42, 6219, 10.1039/c2dt32216a · doi:10.1039/c2dt32216a
  16. Li, 2012, Ruthenium complexes containing bis-benzimidazole derivatives as a new class of apoptosis inducers, Dalton Trans, 41, 1138, 10.1039/C1DT11950H · doi:10.1039/c1dt11950h
  17. Kilpin, 2013, Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands, Dalton Trans, 42, 2008, 10.1039/C2DT32333H · doi:10.1039/c2dt32333h
  18. Khan, 2013, Arene ruthenium dichloro complexes containing isonicotinic ester ligands: synthesis, molecular structure and cytotoxicity, J Organomet Chem, 730, 49, 10.1016/j.jorganchem.2012.10.016 · doi:10.1016/j.jorganchem.2012.10.016
  19. Serratrice, 2012, Cytotoxic gold compounds: synthesis, biological characterization and investigation of their inhibition properties of the zinc finger protein PARP-1, Dalton Trans, 41, 3287, 10.1039/c2dt11913g · DOI
  20. Ronconi, 2009, The Midas touch in cancer chemotherapy: from platinum- to gold-dithiocarbamato complexes, Dalton Trans, 10670, 10.1039/b913597a · doi:10.1039/b913597a
  21. Meker, 2012, High antitumor activity of highly resistant salan-titanium(IV) complexes in nanoparticles: an identified active species, Angew Chem Int Ed Engl, 51, 10515, 10.1002/anie.201205973 · doi:10.1002/anie.201205973

Cited by

See all 515

Metadata

Authors
Muhammad, N., & Guo, Z.
Venue
Current Opinion in Chemical Biology
Publisher
Elsevier BV
Published
2014-04
Volume
19
Pages
144-153
ISSN
1367-5931 (ISSN-L)
OpenAlex
W2090858808
Cited by
515
References
32
FWCI
5.94
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • National Basic Research Program of China (2011CB935800)
  • National Natural Science Foundation of China (21271100, 91213305, 10979019, 21131003, 21021062)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.